Business Context and Reporting Period
This Form 8-K is filed by Sema4 Holdings Corp. (noting the input metadata reference to GeneDx Holdings, the registrant is Sema4) on August 26, 2022, reporting events occurring on August 25, 2022. The filing addresses executive leadership changes and provides updated financial information related to the acquisition of GeneDx, Inc., completed in May 2022.
Key Financial Metrics and Compensation
The filing does not report consolidated revenue, profit, cash flow, or debt metrics for Sema4 Holdings Corp. for the current period. Instead, it references the filing of updated financial exhibits:
- GeneDx Interim Financial Statements: Combined carve-out statements for the three months ended March 31, 2022, and 2021 (Exhibit 99.2).
- Pro Forma Information: Unaudited pro forma combined financial information for the six months ended June 30, 2022, giving effect to the GeneDx acquisition (Exhibit 99.3).
Executive Compensation (Kevin Feeley, new CFO):
- Base Salary: $450,000 annually.
- Target Bonus: 50% of annual base salary.
- Equity Grant: Stock options and restricted stock units with an aggregate grant-date value of $750,000.
Material Changes
Executive Departure: Richard Miao, Interim Chief Financial Officer and Deputy Chief Financial Officer, is departing the company. His last day of employment is September 2, 2022. He will receive accrued and unpaid compensation through that date.
Executive Appointment: Kevin Feeley, previously Senior Vice President of Operations and Head of GeneDx, was appointed Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective August 25, 2022.
Financial Reporting Updates: The filing supersedes or supplements prior financial data regarding the GeneDx acquisition by providing updated interim carve-out statements and pro forma information required for a concurrent Form S-3 registration statement.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, revenue outlook, or specific risk factors beyond the standard disclosure regarding the departure and appointment of officers. The appointment of Mr. Feeley is noted as a strategic move leveraging his prior experience as CFO of BioReference Laboratories, Inc. and GeneDx, Inc., as well as his background in audit practice at KPMG LLP.
Investor Verification Checklist
- Review Exhibit 99.2 for the specific financial performance of GeneDx for the quarter ended March 31, 2022.
- Review Exhibit 99.3 for the unaudited pro forma financial impact of the GeneDx acquisition on Sema4 for the six months ended June 30, 2022.
- Verify the terms of the employment amendment for Kevin Feeley in Exhibit 10.1.
- Confirm the transition timeline for the CFO role between Richard Miao's departure (September 2, 2022) and Feeley's effective date (August 25, 2022).